The effect of ZAP-70 expression on disease progression in early-stage (Binet A) B-CLL patients


Üre Ü., AR M. C., BAŞLAR Z., Soysal T., ÖNGÖREN Ş., Gülseven M., ...Daha Fazla

Trakya Universitesi Tip Fakultesi Dergisi, cilt.26, sa.4, ss.317-321, 2009 (SCI-Expanded, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 4
  • Basım Tarihi: 2009
  • Dergi Adı: Trakya Universitesi Tip Fakultesi Dergisi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.317-321
  • Anahtar Kelimeler: Chronic lymphocytic leukemia, ZAP-70, prognosis
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objectives: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with various clinical findings. Prognostic markers predicting the clinical outcome in early-stage CLL would play a major role in disease management. Various studies have shown that zeta-associated protein 70 (ZAP-70) provides significant prognostic information. This retrospective, single-centre study evaluates the effect of ZAP-70 on disease progression in early-stage B-CLL. Patients and Methods: Fifty early-stage patients with a median age of 66 years (range 47-86 years) were enrolled in this study. ZAP-70 expression was measured in peripheral blood samples using flow cytometry. Cut-off value for ZAP-70 positivity was set at 20%. Results: Treatment had to be initiated in 21 of the 50 patients within a median of 42 months. The median time to initial treatment was 24 months. Twelve of the 50 patients (24%) were ZAP-70 positive. Ten of the 12 patients (83%) in the ZAP(+) group and 11 of the 38 patients (29%) in the ZAP(-) group required treatment on follow-up. The median treatment-free interval in ZAP(+) and ZAP(-) groups were 25 and 72 months, respectively (p=0.0001). Conclusion: ZAP-70 provides significant prognostic information and predicts treatment requirement in early-stage B-CLL patients. Ongoing studies will highlight the need for a different management policy of ZAP-70(+) early-stage CLL. © Medical Journal of Trakya University. Published by Ekin Medical Publishing. All rights reserved.